91±¬ÁϳÉÈËƬ

Edwin Moses is a highly regarded life sciences entrepreneur and board-level executive with over 30 years of experience building and scaling innovative biotech companies across Europe and the United States. He is best known for his tenure as CEO of Ablynx NV, which he led from early-stage through to a landmark $4.8 billion acquisition by Sanofi in 2018, and as CEO of Oxford Asymmetry International, which he sold to Evotec for £316 million. He led both companies through successful IPOs on the London Stock Exchange, Euronext and NASDAQ, and has raised over €700 million in equity and debt financing throughout his career. Beyond his executive roles, Edwin has made a substantial impact as a chairman and board member, contributing to over 20 European life sciences companies. He currently serves or has recently served as Chairman of Avantium NV, Achilles Therapeutics, LabGenius, NanoSyrinx, and 91±¬ÁϳÉÈËƬ Therapeutics, among others, consistently bringing strategic clarity, fundraising expertise and commercial acumen to companies at pivotal stages of their development.